115 related articles for article (PubMed ID: 1434216)
1. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
[TBL] [Abstract][Full Text] [Related]
2. [Colony-stimulating factor activity in malignant pleural effusions and its augmentation by local administration of interleukin 2].
Nakanishi M; Sone S; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Jul; 29(7):824-8. PubMed ID: 1920977
[TBL] [Abstract][Full Text] [Related]
3. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
Yanagawa H; Sone S; Nii A; Fukuta K; Nakanishi M; Maeda K; Honda M; Ogura T
Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
[TBL] [Abstract][Full Text] [Related]
5. [Experimental and clinical studies on intrapleural instillations of interleukin-2 (IL-2) in patients with malignant pleural effusion].
Suzuki H
Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1922-31. PubMed ID: 2608022
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
7. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
8. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
Mao G; Gao Z; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
[TBL] [Abstract][Full Text] [Related]
9. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
10. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
11. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
Li DJ
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
[TBL] [Abstract][Full Text] [Related]
12. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
13. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
[TBL] [Abstract][Full Text] [Related]
14. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
[TBL] [Abstract][Full Text] [Related]
15. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.
Limb GA; Meager A; Woolley J; Wadhwa M; Biggerstaff J; Brown KA; Wolstencroft RA
Immunology; 1989 Dec; 68(4):514-9. PubMed ID: 2514140
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
17. Influence of various cytokines on the induction of lymphokine-activated killer cells.
Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma].
Hazama S; Oka M; Yoshino S; Iizuka N; Wadamori K; Yamamoto K; Hirazawa K; Wang F; Ogura Y; Masaki Y
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1595-7. PubMed ID: 7574768
[TBL] [Abstract][Full Text] [Related]
19. Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokine predominance in tumour-associated mononuclear cells from lung cancer patients.
Takeuchi E; Yanagawa H; Suzuki Y; Shinkawa K; Bando H; Sone S
Cytokine; 2001 Jan; 13(2):119-23. PubMed ID: 11145853
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells.
Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S
Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
